UPDATE: Cytosorbents (CTSO) Tops Q2 EPS View
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
CytoSorbents Reports Steady Growth in Q2 2015
August 13, 2015 4:15 PM EDTMONMOUTH JUNCTION, N.J., Aug. 13, 2015 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to reduce deadly uncontrolled inflammation in hospitalized patients around the world, reported financial and operational results for the three and six months ended June 30, 2015.
Highlights Potential Catalysts for Accelerated Growth in the Second Half of 2015
Recent Financial Highlights:
Product revenues for the second quarter of... More